Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax

Journal of Infectious Diseases

Volumn 198, Issue 10, 2008, Pages 1558-1564

  Suwanarusk, R ^a   Chavchich, M ^b   Russell, B ^a   Jaidee, A ^c   Chalfein, F ^e   Barends, M ^c   Prasetyorini, B ^g   Kenangalem, E ^e,f   Piera, K A ^a   Lek Uthai, U ^d   Anstey, N M ^a   Tjitra, E ^g   Nosten, F ^c,d,h   Cheng, Q ^b   Price, R N ^a,h  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b AUSTRALIAN ARMY MALARIA INSTITUTE   (Australia)

^c SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f District Health Authority   (Indonesia)

^g NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^h JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTESUNATE; CHLOROQUINE; MEFLOQUINE; PIPERAQUINE;

ALLELE; ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; HUMAN; IC 50; IN VITRO STUDY; INDONESIA; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PLASMODIUM VIVAX; PRIORITY JOURNAL; SOUTHEAST ASIA; THAILAND; WILD TYPE;

ANIMALS; ANTIMALARIALS; DRUG RESISTANCE, MULTIPLE; GENE DOSAGE; GENOTYPE; INHIBITORY CONCENTRATION 50; MALARIA, VIVAX; P-GLYCOPROTEIN; PARASITIC SENSITIVITY TESTS; PLASMODIUM VIVAX; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 54949093986     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/592451     Document Type: Article

References (34)

1. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 2007; 77:79-87.
2. Baird JK. Neglect of Plasmodium vivax malaria. Trends Parasitol 2007;23:533-9.
3. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 2001; 64:97-106.
4. Tjitra E, Anstey NM, Sugiarto P, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 2008; 5:e136.
5. Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistance to chloroquine? Lancet 1989; 2:1183-4.
6. Baird JK, Basri H, Purnomo, et al. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg 1991; 44:547-52.
7. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine- pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob Agents Chemother 2002; 46:3947-53.
8. Sumawinata IW, Bernadeta, Leksana B, et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg 2003; 68:416-20.
9. Ratcliff A, Siswantoro H, Kenangalem E, et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg 2007; 101:351-9.
10. Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 2004; 48:4075-83.
11. Maguire JD, Krisin, Marwoto H, Richie TL, Fryauff DJ, Baird JK. Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia. Clin Infect Dis 2006; 42:1067-72.
12. Hasugian AR, Purba HL, Kenangalem E, et al. Dihydroartemisinin- piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis 2007; 44:1067-74.
13. Marfurt J, Mueller I, Sie A, et al. Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea. Am J Trop Med Hyg 2007; 77:947-54.
14. Baird JK, Leksana B, Masbar S, et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg 1997; 56:621-6.
15. Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J Infect Dis 2007; 195:934-41.
16. Imwong M, Snounou G, Pukrittayakamee S, et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 2007; 195:927-33.
17. Russell B, Chalfein F, Prasetyorini B, et al. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob Agents Chemother 2008; 52:1040-5.
18. Suwanarusk R, Russell B, Chavchich M, et al. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS ONE 2007; 2:e1089.
19. Luxemburger C, van Vugt M, Jonathan S, et al. Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg 1999; 93:433-8.
20. Ratcliff A, Siswantoro H, Kenangalem E, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007; 369:757-65.
21. Kosaisavee V, Suwanarusk R, Nosten F, et al. Plasmodium vivax: isotopic, PicoGreen, and microscopic assays for measuring chloroquine sensitivity in fresh and cryopreserved isolates. Exp Parasitol 2006; 114:34-9.
22. Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 2000; 6:861-71.
23. Plowe CV, Cortese JF, Djimde A, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 1997; 176:1590-6.
24. Wilson CM, Volkman SK, Thaithong S, et al. Amplification of pfmdr 1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand. Mol Biochem Parasitol 1993; 57:151-60.
25. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 2000; 403:906-9.
26. Price RN, Cassar C, Brockman A, et al. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother 1999; 43:2943-9.
27. Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004; 364:438-47.
28. Price RN, Uhlemann AC, Vugt M, et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 2006; 42:1570-7.
29. Pickard AL, Wongsrichanalai C, Purfield A, et al. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob Agents Chemother 2003; 47:2418-23.
30. Nomura T, Carlton JM, Baird JK, et al. Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria. J Infect Dis 2001; 183:1653-61.
31. Nosten F, van Vugt M, Price R, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000; 356:297-302.
32. Chotivanich K, Udomsangpetch R, Chierakul W, et al. In vitro efficacy of antimalarial drugs against Plasmodium vivax on the western border of Thailand. Am J Trop Med Hyg 2004; 70:395-7.
33. Uhlemann AC, McGready R, Ashley EA, et al. Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. J Infect Dis 2007; 195:134-41.
34. Imwong M, Pukrittayakamee S, Pongtavornpinyo W, et al. Gene amplification of Plasmodium vivax multidrug resistance 1 gene in Thailand, Laos, and Myanmar. Antimicrob Agents Chemother 2008; 52:2657-9.